D&O Ongoing Disclosures – Multiple

Ongoing Disclosure Notice
Disclosure of Directors and Senior Managers Relevant Interests
Sections 297(2) and 298(2), Financial Markets Conduct Act 2013
To NZX Limited; and
Name of listed issuer:
Green Cross Health Limited
Date this disclosure made:
22-Dec-17
Date of last disclosure:
28-Jun-17
Director or senior manager giving disclosure
Full name(s):
John Andrew Bagnall
Name of listed issuer:
Green Cross Health Limited
Name of related body corporate (if applicable):
N/A
Position held in listed issuer:
Director
Summary of acquisition or disposal of relevant interest (excluding specified derivatives)
Class of affected quoted financial products:
Fully Paid Ordinary Shares (OS)
Nature of the affected relevant interest(s):
Holder of all the shares in LPL
Trustee Limited
For that relevant interest-
Number held in class before acquisition or disposal:
44,978,654
Number held in class after acquisition or disposal:
45,935,821
Current registered holder(s):
LPL Trustee Limited
Registered holder(s) once transfers are registered:
LPL Trustee Limited
Summary of acquisition or disposal of specified derivatives relevant interest (if applicable)
Type of affected derivative:
Class of underlying financial products:
Details of affected derivative-
The notional value of the derivative (if any) or the notional amount of underlying financial
products (if any):
A statement as to whether the derivative is cash settled or physically settled:
Maturity date of the derivative (if any):
Expiry date of the derivative(if any):
The price specified in the terms of the derivative (if any):
Any other details needed to understand how the amount of the consideration payable
under the derivative or the value of the derivative is affected by the value of the
underlying financial products:
For that derivative,-
Parties to the derivative:
If the director or senior manager is not a party to the derivative, the nature of the relevant
interest in the derivative:

Details of transactions giving rise to acquisition or disposal
Total number of transactions to which notice relates: 1
Details of transactions requiring disclosure-
Date of transaction:
22-Dec-17
Nature of transaction:
Acquisition of 957,167 ordinary
shares by LPL Trustee Limited on
reinvestment of dividends under
the Dividend Reinvestment Plan of
Green Cross Health Limited.
Shareholding now 32.09% of total
shares.
Name of any other party or parties to the transaction (if known):
The consideration, expressed in New Zealand dollars, paid or received for the acquisition
or disposal. If the consideration was not in cash and cannot be readily by converted into a
cash value, describe the consideration:
$1,574,252.56
Number of financial products to which the transaction related:
If the issuer has a financial products trading policy that prohibits directors or senior
managers from trading during any period without written clearance (a closed period)
include the following details—
Whether relevant interests were acquired or disposed of during a closed period:
Whether prior written clearance was provided to allow the acquisition or disposal to
proceed during the closed period:
Date of the prior written clearance (if any):
Summary of other relevant interests after acquisition or disposal:
Class of quoted financial products:
Nature of relevant interest:
For that relevant interest,-
Number held in class:
Current registered holder(s):
For a derivative relevant interest,-
Type of derivative:
Details of derivative,-
The notional value of the derivative (if any) or the notional amount of underlying financial
products (if any):
A statement as to whether the derivative is cash settled or physically settled:
Maturity date of the derivative (if any):
Expiry date of the derivative (if any):
The price's specified terms (if any):
Any other details needed to understand how the amount of the consideration payable
under the derivative or the value of the derivative is affected by the value of the
underlying financial products:
For that derivative relevant interest,-
Parties to the derivative:
If the director or senior manager is not a party to the derivative, the nature of the relevant
interest in the derivative:
Certification
I certify that, to the best of my knowledge and belief, the information contained in this
disclosure is correct and that I am duly authorised to make this disclosure by all persons
for whom it is made.
Signature of director or officer:
Date of signature:
or
Signature of person authorised to sign on behalf of director or officer:
Date of signature: 22-Dec-17
Name and title of authorised person:
Steve Browning, Chief Financial
Officer - Green Cross Health
Limited

---

Ongoing Disclosure Notice
Disclosure of Directors and Senior Managers Relevant Interests
Sections 297(2) and 298(2), Financial Markets Conduct Act 2013
To NZX Limited; and
Name of listed issuer:
Green Cross Health Limited
Date this disclosure made:
22-Dec-17
Date of last disclosure:
28-Jun-17
Director or senior manager giving disclosure
Full name(s):
Anthony William Edwards
Name of listed issuer:
Green Cross Health Limited
Name of related body corporate (if applicable):
Position held in listed issuer:
Director
Summary of acquisition or disposal of relevant interest (excluding specified derivatives)
Class of affected quoted financial products:
Fully Paid Ordinary Shares (OS)
Nature of the affected relevant interest(s):
Benefical interest held by Anthony William
Edwards
For that relevant interest-
Number held in class before acquisition or disposal:
97,602
Number held in class after acquisition or disposal:
99,535
Current registered holder(s):
Mr A W Edwards
Registered holder(s) once transfers are registered:
Mr A W Edwards
Summary of acquisition or disposal of specified derivatives relevant interest (if applicable)
Type of affected derivative:
Class of underlying financial products:
Details of affected derivative-
The notional value of the derivative (if any) or the notional amount of underlying financial
products (if any):
A statement as to whether the derivative is cash settled or physically settled:
Maturity date of the derivative (if any):
Expiry date of the derivative(if any):
The price specified in the terms of the derivative (if any):
Any other details needed to understand how the amount of the consideration payable
under the derivative or the value of the derivative is affected by the value of the underlying
financial products:
For that derivative,-
Parties to the derivative:
If the director or senior manager is not a party to the derivative, the nature of the relevant
interest in the derivative:

Details of transactions giving rise to acquisition or disposal
Total number of transactions to which notice relates: 1
Details of transactions requiring disclosure-
Date of transaction:
22-Dec-17
Nature of transaction:
Acquisition of 1,933 ordinary shares by
Anthony Edwards on reinvestment of
dividends under the Dividend
Reinvestment Plan of Green Cross
Health Limited. Shareholding now 0.07%
of total shares.
Name of any other party or parties to the transaction (if known):
The consideration, expressed in New Zealand dollars, paid or received for the acquisition
or disposal. If the consideration was not in cash and cannot be readily by converted into a
cash value, describe the consideration:
$3,178.80
Number of financial products to which the transaction related:
If the issuer has a financial products trading policy that prohibits directors or senior
managers from trading during any period without written clearance (a closed period)
include the following details—
Whether relevant interests were acquired or disposed of during a closed period:
Whether prior written clearance was provided to allow the acquisition or disposal to
proceed during the closed period:
Date of the prior written clearance (if any):
Summary of other relevant interests after acquisition or disposal:
Class of quoted financial products:
Nature of relevant interest:
For that relevant interest,-
Number held in class:
Current registered holder(s):
For a derivative relevant interest,-
Type of derivative:
Details of derivative,-
The notional value of the derivative (if any) or the notional amount of underlying financial
products (if any):
A statement as to whether the derivative is cash settled or physically settled:
Maturity date of the derivative (if any):
Expiry date of the derivative (if any):
The price's specified terms (if any):
Any other details needed to understand how the amount of the consideration payable
under the derivative or the value of the derivative is affected by the value of the underlying
financial products:
For that derivative relevant interest,-
Parties to the derivative:
If the director or senior manager is not a party to the derivative, the nature of the relevant
interest in the derivative:
Certification
I certify that, to the best of my knowledge and belief, the information contained in this
disclosure is correct and that I am duly authorised to make this disclosure by all persons
for whom it is made.
Signature of director or officer:
Date of signature:
or
Signature of person authorised to sign on behalf of director or officer:
Date of signature:
22-Dec-17
Name and title of authorised person:
Steve Browning, Chief Financial Officer -
Green Cross Health Limited

---

Ongoing Disclosure Notice
Disclosure of Directors and Senior Managers Relevant Interests
Sections 297(2) and 298(2), Financial Markets Conduct Act 2013
To NZX Limited; and
Name of listed issuer:
Green Cross Health Limited
Date this disclosure made:
22-Dec-17
Date of last disclosure:
28-Jun-17
Director or senior manager giving disclosure
Full name(s):
Kenneth Arthur Orr
Name of listed issuer:
Green Cross Health Limited
Name of related body corporate (if applicable):
N/A
Position held in listed issuer:
Director
Summary of acquisition or disposal of relevant interest (excluding specified derivatives)
Class of affected quoted financial products:
Fully Paid Ordinary Shares (OS)
Nature of the affected relevant interest(s):
Orrs Pharmacies Ltd and Orrs
Kaipara Pharmacies Ltd
For that relevant interest-
Number held in class before acquisition or disposal:
Orrs Pharmacies Ltd - 223,618
and Orrs Kaipara Pharmacies Ltd -
364,813
Number held in class after acquisition or disposal:
Orrs Pharmacies Ltd - 228,046
and Orrs Kaipara Pharmacies Ltd -
372,037
Current registered holder(s):
Orrs Pharmacies Ltd and Orrs
Kaipara Pharmacies Ltd
Registered holder(s) once transfers are registered:
Orrs Pharmacies Ltd and Orrs
Kaipara Pharmacies Ltd
Summary of acquisition or disposal of specified derivatives relevant interest (if applicable)
Type of affected derivative:
Class of underlying financial products:
Details of affected derivative-
The notional value of the derivative (if any) or the notional amount of underlying financial
products (if any):
A statement as to whether the derivative is cash settled or physically settled:
Maturity date of the derivative (if any):
Expiry date of the derivative(if any):
The price specified in the terms of the derivative (if any):
Any other details needed to understand how the amount of the consideration payable
under the derivative or the value of the derivative is affected by the value of the underlying
financial products:
For that derivative,-
Parties to the derivative:
If the director or senior manager is not a party to the derivative, the nature of the relevant
interest in the derivative:

Details of transactions giving rise to acquisition or disposal
Total number of transactions to which notice relates:
2
Details of transactions requiring disclosure-
Date of transaction:
22-Dec-17
Nature of transaction:
Acquisition of 4,428 ordinary
shares by Orrs Pharmacies Ltd &
7,224 ordinary shares by Orrs
Kaipara Pharmacies Ltd on
reinvestment of dividends under
the Dividend Reinvestment Plan of
Green Cross Health Limited.
Shareholding now 0.42% of total
shares.
Name of any other party or parties to the transaction (if known):
The consideration, expressed in New Zealand dollars, paid or received for the acquisition
or disposal. If the consideration was not in cash and cannot be readily by converted into a
cash value, describe the consideration:
$19,164.61
Number of financial products to which the transaction related:
If the issuer has a financial products trading policy that prohibits directors or senior
managers from trading during any period without written clearance (a closed period)
include the following details—
Whether relevant interests were acquired or disposed of during a closed period:
Whether prior written clearance was provided to allow the acquisition or disposal to
proceed during the closed period:
Date of the prior written clearance (if any):
Summary of other relevant interests after acquisition or disposal:
Class of quoted financial products:
Nature of relevant interest:
For that relevant interest,-
Number held in class:
Current registered holder(s):
For a derivative relevant interest,-
Type of derivative:
Details of derivative,-
The notional value of the derivative (if any) or the notional amount of underlying financial
products (if any):
A statement as to whether the derivative is cash settled or physically settled:
Maturity date of the derivative (if any):
Expiry date of the derivative (if any):
The price's specified terms (if any):
Any other details needed to understand how the amount of the consideration payable
under the derivative or the value of the derivative is affected by the value of the underlying
financial products:
For that derivative relevant interest,-
Parties to the derivative:
If the director or senior manager is not a party to the derivative, the nature of the relevant
interest in the derivative:
Certification
I certify that, to the best of my knowledge and belief, the information contained in this
disclosure is correct and that I am duly authorised to make this disclosure by all persons
for whom it is made.
Signature of director or officer:
Date of signature:
or
Signature of person authorised to sign on behalf of director or officer:
Date of signature:
22-Dec-17
Name and title of authorised person:
Steve Browning, Chief Financial
Officer - Green Cross Health
Limited

---

Ongoing Disclosure Notice
Disclosure of Directors and Senior Managers Relevant Interests
Sections 297(2) and 298(2), Financial Markets Conduct Act 2013
To NZX Limited; and
Name of listed issuer:
Green Cross Health Limited
Date this disclosure made:
22-Dec-17
Date of last disclosure:
28-Jun-17
Director or senior manager giving disclosure
Full name(s):
Grant Clayton Bai
Name of listed issuer:
Green Cross Health Limited
Name of related body corporate (if applicable):
Position held in listed issuer:
CEO - Pharmacy
Summary of acquisition or disposal of relevant interest (excluding specified derivatives)
Class of affected quoted financial products:
Fully Paid Ordinary Shares (OS)
Nature of the affected relevant interest(s):
Legal Owner & Registered holder
For that relevant interest-
Number held in class before acquisition or disposal:
1,045,520
Number held in class after acquisition or disposal:
1,066,224
Current registered holder(s):
Grant Bai, Christine Bai and Barrie
Campbell
Registered holder(s) once transfers are registered:
Grant Bai, Christine Bai and Barrie
Campbell
Summary of acquisition or disposal of specified derivatives relevant interest (if applicable)
Type of affected derivative:
Class of underlying financial products:
Details of affected derivative-
The notional value of the derivative (if any) or the notional amount of underlying financial
products (if any):
A statement as to whether the derivative is cash settled or physically settled:
Maturity date of the derivative (if any):
Expiry date of the derivative(if any):
The price specified in the terms of the derivative (if any):
Any other details needed to understand how the amount of the consideration payable
under the derivative or the value of the derivative is affected by the value of the underlying
financial products:
For that derivative,-
Parties to the derivative:
If the director or senior manager is not a party to the derivative, the nature of the relevant
interest in the derivative:
Details of transactions giving rise to acquisition or disposal
Total number of transactions to which notice relates: 1

Details of transactions requiring disclosure-
Date of transaction:
22-Dec-17
Nature of transaction:
Acquisition of 20,704 ordinary
shares on reinvestment of dividends
under the Dividend Reinvestment
Plan of Green Cross Health Limited
Name of any other party or parties to the transaction (if known):
The consideration, expressed in New Zealand dollars, paid or received for the acquisition
or disposal. If the consideration was not in cash and cannot be readily by converted into a
cash value, describe the consideration:
$34,051.54
Number of financial products to which the transaction related:
If the issuer has a financial products trading policy that prohibits directors or senior
managers from trading during any period without written clearance (a closed period)
include the following details—
Whether relevant interests were acquired or disposed of during a closed period:
Whether prior written clearance was provided to allow the acquisition or disposal to
proceed during the closed period:
Date of the prior written clearance (if any):
Summary of other relevant interests after acquisition or disposal:
Class of quoted financial products:
Nature of relevant interest:
For that relevant interest,-
Number held in class:
Current registered holder(s):
For a derivative relevant interest,-
Type of derivative:
Details of derivative,-
The notional value of the derivative (if any) or the notional amount of underlying financial
products (if any):
A statement as to whether the derivative is cash settled or physically settled:
Maturity date of the derivative (if any):
Expiry date of the derivative (if any):
The price's specified terms (if any):
Any other details needed to understand how the amount of the consideration payable
under the derivative or the value of the derivative is affected by the value of the underlying
financial products:
For that derivative relevant interest,-
Parties to the derivative:
If the director or senior manager is not a party to the derivative, the nature of the relevant
interest in the derivative:
Certification
I certify that, to the best of my knowledge and belief, the information contained in this
disclosure is correct and that I am duly authorised to make this disclosure by all persons
for whom it is made.
Signature of director or officer:
Date of signature:
or
Signature of person authorised to sign on behalf of director or officer:
Date of signature:
22-Dec-17
Name and title of authorised person:
Steve Browning, Chief Financial
Officer - Green Cross Health
Limited

---

Ongoing Disclosure Notice
Disclosure of Directors and Senior Managers Relevant Interests
Sections 297(2) and 298(2), Financial Markets Conduct Act 2013
To NZX Limited; and
Name of listed issuer:
Green Cross Health Limited
Date this disclosure made:
22-Dec-17
Date of last disclosure:
28-Jun-17
Director or senior manager giving disclosure
Full name(s):
Jason Reeves
Name of listed issuer:
Green Cross Health Limited
Name of related body corporate (if applicable):
Position held in listed issuer:
GM Pharmacy - Operations &
Merchandise
Summary of acquisition or disposal of relevant interest (excluding specified derivatives)
Class of affected quoted financial products:
Fully Paid Ordinary Shares (OS)
Nature of the affected relevant interest(s):
Legal Owner & Registered holder
For that relevant interest-
Number held in class before acquisition or disposal:
2,215
Number held in class after acquisition or disposal:
2,259
Current registered holder(s):
Mr JR Reeves
Registered holder(s) once transfers are registered:
Mr JR Reeves
Summary of acquisition or disposal of specified derivatives relevant interest (if applicable)
Type of affected derivative:
Class of underlying financial products:
Details of affected derivative-
The notional value of the derivative (if any) or the notional amount of underlying financial
products (if any):
A statement as to whether the derivative is cash settled or physically settled:
Maturity date of the derivative (if any):
Expiry date of the derivative(if any):
The price specified in the terms of the derivative (if any):
Any other details needed to understand how the amount of the consideration payable
under the derivative or the value of the derivative is affected by the value of the underlying
financial products:
For that derivative,-
Parties to the derivative:
If the director or senior manager is not a party to the derivative, the nature of the relevant
interest in the derivative:
Details of transactions giving rise to acquisition or disposal
Total number of transactions to which notice relates: 1

Details of transactions requiring disclosure-
Date of transaction:
22-Dec-17
Nature of transaction:
Acquisition of 44 ordinary shares on
reinvestment of dividends under the
Dividend Reinvestment Plan of
Green Cross Health Limited
Name of any other party or parties to the transaction (if known):
The consideration, expressed in New Zealand dollars, paid or received for the acquisition
or disposal. If the consideration was not in cash and cannot be readily by converted into a
cash value, describe the consideration:
$72.14
Number of financial products to which the transaction related:
If the issuer has a financial products trading policy that prohibits directors or senior
managers from trading during any period without written clearance (a closed period)
include the following details—
Whether relevant interests were acquired or disposed of during a closed period:
Whether prior written clearance was provided to allow the acquisition or disposal to
proceed during the closed period:
Date of the prior written clearance (if any):
Summary of other relevant interests after acquisition or disposal:
Class of quoted financial products:
Partly paid redeemable ordinary
shares (ROS)
Nature of relevant interest:beneficial owner
For that relevant interest,-
Number held in class:33,334
Current registered holder(s):
Life Pharmacy Trustee Company
Limited
For a derivative relevant interest,-
Type of derivative:
Details of derivative,-
The notional value of the derivative (if any) or the notional amount of underlying financial
products (if any):
A statement as to whether the derivative is cash settled or physically settled:
Maturity date of the derivative (if any):
Expiry date of the derivative (if any):
The price's specified terms (if any):
Any other details needed to understand how the amount of the consideration payable
under the derivative or the value of the derivative is affected by the value of the underlying
financial products:
For that derivative relevant interest,-
Parties to the derivative:
If the director or senior manager is not a party to the derivative, the nature of the relevant
interest in the derivative:
Certification
I certify that, to the best of my knowledge and belief, the information contained in this
disclosure is correct and that I am duly authorised to make this disclosure by all persons
for whom it is made.
Signature of director or officer:
Date of signature:
or
Signature of person authorised to sign on behalf of director or officer:
Date of signature:
22-Dec-17
Name and title of authorised person:
Steve Browning, Chief Financial
Officer - Green Cross Health
Limited

---

Ongoing Disclosure Notice
Disclosure of Directors and Senior Managers Relevant Interests
Sections 297(2) and 298(2), Financial Markets Conduct Act 2013
To NZX Limited; and
Name of listed issuer:
Green Cross Health Limited
Date this disclosure made:
22-Dec-17
Date of last disclosure:
28-Jun-17
Director or senior manager giving disclosure
Full name(s):
Peter Miles Merton
Name of listed issuer:
Green Cross Health Limited
Name of related body corporate (if applicable):
Position held in listed issuer:
Director
Summary of acquisition or disposal of relevant interest (excluding specified derivatives)
Class of affected quoted financial products:
Fully Paid Ordinary Shares (OS)
Nature of the affected relevant interest(s):
Holder of 49% of the shares in Cape
Healthcare Limited.
For that relevant interest-
Number held in class before acquisition or disposal:
44,950,837
Number held in class after acquisition or disposal:
45,840,983
Current registered holder(s):
Cape Healthcare Limited
Registered holder(s) once transfers are registered:
Cape Healthcare Limited
Summary of acquisition or disposal of specified derivatives relevant interest (if applicable)
Type of affected derivative:
Class of underlying financial products:
Details of affected derivative-
The notional value of the derivative (if any) or the notional amount of underlying financial
products (if any):
A statement as to whether the derivative is cash settled or physically settled:
Maturity date of the derivative (if any):
Expiry date of the derivative(if any):
The price specified in the terms of the derivative (if any):
Any other details needed to understand how the amount of the consideration payable
under the derivative or the value of the derivative is affected by the value of the underlying
financial products:
For that derivative,-
Parties to the derivative:
If the director or senior manager is not a party to the derivative, the nature of the relevant
interest in the derivative:

Details of transactions giving rise to acquisition or disposal
Total number of transactions to which notice relates: 1
Details of transactions requiring disclosure-
Date of transaction:
22-Dec-17
Nature of transaction:
Acquisition of 890,146 ordinary shares by
Cape Healthcare Limited on reinvestment
of dividends under the Dividend
Reinvestment Plan of Green Cross
Health Limited. Shareholding now 32.02%
of total shares.
Name of any other party or parties to the transaction (if known):
The consideration, expressed in New Zealand dollars, paid or received for the acquisition
or disposal. If the consideration was not in cash and cannot be readily by converted into a
cash value, describe the consideration:
$1,464,023.13
Number of financial products to which the transaction related:
If the issuer has a financial products trading policy that prohibits directors or senior
managers from trading during any period without written clearance (a closed period)
include the following details—
Whether relevant interests were acquired or disposed of during a closed period:
Whether prior written clearance was provided to allow the acquisition or disposal to
proceed during the closed period:
Date of the prior written clearance (if any):
Summary of other relevant interests after acquisition or disposal:
Class of quoted financial products:
Nature of relevant interest:
For that relevant interest,-
Number held in class:
Current registered holder(s):
For a derivative relevant interest,-
Type of derivative:
Details of derivative,-
The notional value of the derivative (if any) or the notional amount of underlying financial
products (if any):
A statement as to whether the derivative is cash settled or physically settled:
Maturity date of the derivative (if any):
Expiry date of the derivative (if any):
The price's specified terms (if any):
Any other details needed to understand how the amount of the consideration payable
under the derivative or the value of the derivative is affected by the value of the underlying
financial products:
For that derivative relevant interest,-
Parties to the derivative:
If the director or senior manager is not a party to the derivative, the nature of the relevant
interest in the derivative:
Certification
I certify that, to the best of my knowledge and belief, the information contained in this
disclosure is correct and that I am duly authorised to make this disclosure by all persons
for whom it is made.
Signature of director or officer:
Date of signature:
or
Signature of person authorised to sign on behalf of director or officer:
Date of signature:
22-Dec-17
Name and title of authorised person:
Steve Browning, Chief Financial Officer -
Green Cross Health Limited